Retraction
Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
Paper Information
Record ID:
46490
Author(s):
Journal:
Publication Date:
November 10, 2021
Retraction Date:
July 31, 2023
(2.3 years years ago)
Subjects:
Institution:
Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, 300211, ChinaCountry:
🇨🇳 ChinaArticle Type:
Publisher:
Springer - Nature Publishing Group
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1038/s41388-023-02790-8Additional Notes:
see also: https://pubpeer.com/publications/90FF288A6F0E71054998B09519903B
Citations (27)
27
Total Citations10
Post-Retraction(37.0%)
17
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
1
Within 30 days
7
Within 1 year
0
After 2+ years
592
Days since retraction (latest)
Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15
Chenglin Han, Bin Yang, Yuxuan Deng et al. (10 authors)
Chinese Medicine
Open Access
Published: Mar 2025
1 citation
1 citation
592 days after retraction
UBE2S, downregulated by miR-152-3p, facilitates prostate cancer progression through the PTEN-mediated AKT/mTOR pathway
Chunhui Wang, Gang Zhang, Ying Jiang et al. (5 authors)
Human Molecular Genetics
Published: Jan 2025
525 days after retraction
Bavdegalutamide (ARV-110): a potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer
Lin Ma, Xin Han
Elsevier eBooks
Published: Nov 2024
1 citation
1 citation
459 days after retraction
A potent new-scaffold androgen receptor antagonist discovered on the basis of a MIEC-SVM model
Xinyue Wang, Xin Chai, Luhu Shan et al. (8 authors)
Acta Pharmacologica Sinica
Published: May 2024
7 citations
7 citations
289 days after retraction
An androgen receptor-based signature to predict prognosis and identification of ORC1 as a therapeutical target for prostate adenocarcinoma
Linjin Li, Dake Chen, Xiang Chen et al. (8 authors)
PeerJ
Open Access
Published: Mar 2024
1 citation
1 citation
242 days after retraction
Androgen‐repressed lncRNA LINC01126 drives castration‐resistant prostate cancer by regulating the switch between O‐GlcNAcylation and phosphorylation of androgen receptor
Yi Cai, Minfeng Chen, Yuchen Gong et al. (10 authors)
Clinical and Translational Medicine
Open Access
Published: Jan 2024
8 citations
8 citations
154 days after retraction
The lncRNA Signature Associated with Basement Membrane as a Novel Biomarker of Prognostic Significance and Identification for Clear Cell Renal Cell Carcinoma
屹森 黎
Advances in Clinical Medicine
Published: Jan 2024
154 days after retraction
The role of <scp>KDM4A‐mediated</scp> histone methylation on temozolomide resistance in glioma cells through the <scp>HUWE1</scp>/<scp>ROCK2</scp> axis
Xi-xi Li, Jia‐Kun Xu, Weijie Su et al. (8 authors)
The Kaohsiung Journal of Medical Sciences
Open Access
Published: Oct 2023
2 citations
2 citations
85 days after retraction
The roles of FLOT1 in human diseases (Review)
Ziqing Zhan, Meng Ye, Xiaofeng Jin
Molecular Medicine Reports
Open Access
Published: Sep 2023
13 citations
13 citations
53 days after retraction
Editorial: Mechanisms of action of natural antisense transcripts on the post-transcriptional regulation of sense protein coding gene expression during development and in cancer
Tominori Kimura, Gian Gaetano Tartaglia
Frontiers in Molecular Biosciences
Open Access
Published: Aug 2023
30 days after retraction
Long non-coding RNA-targeting therapeutics: discovery and development update
Olga Khorkova, Jack Stahl, Aswathy Joji et al. (6 authors)
Expert Opinion on Drug Discovery
Published: Jul 2023
16 citations
16 citations
12 days before retraction
Long non‑coding RNAs as potential therapeutic targets in non‑small cell lung cancer (Review)
Peiyu Tang, Dejuan Sun, Wei Xu et al. (5 authors)
International Journal of Molecular Medicine
Open Access
Published: Jun 2023
6 citations
6 citations
41 days before retraction
Role of Circular RNAs in Prostate Cancer
Feng Chen, F. Zhang, Yongqiang Liu et al. (4 authors)
Current Medicinal Chemistry
Published: Jun 2023
1 citation
1 citation
60 days before retraction
Post-transcriptional modification of m6A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
Yang Li, Shimiao Zhu, Yutong Chen et al. (15 authors)
Cell Death and Disease
Open Access
Published: Apr 2023
23 citations
23 citations
98 days before retraction
Machine learning-based construction of a ferroptosis and necroptosis associated lncRNA signature for predicting prognosis and immunotherapy response in hepatocellular cancer
Lei Zhao, Zhixuan You, Zhixun Bai et al. (4 authors)
Frontiers in Oncology
Open Access
Published: Apr 2023
7 citations
7 citations
102 days before retraction
The functional roles of m6A modification in prostate cancer
Fa Zhang, Feng Chen, Chao Wang et al. (4 authors)
PROTEOMICS - CLINICAL APPLICATIONS
Published: Apr 2023
3 citations
3 citations
104 days before retraction
Identification of a cuproptosis and copper metabolism gene–related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma
Wei Yuan, Junhao Xiao, Jiansong Zhang et al. (6 authors)
Frontiers in Oncology
Open Access
Published: Mar 2023
8 citations
8 citations
125 days before retraction
E2F1-mediated KDM4A-AS1 up-regulation promotes EMT of hepatocellular carcinoma cells by recruiting ILF3 to stabilize AURKA mRNA
Haoming Shen, Di Zhang, Ping Xiao et al. (5 authors)
Cancer Gene Therapy
Open Access
Published: Mar 2023
15 citations
15 citations
126 days before retraction
The crosstalk between ubiquitination and endocrine therapy
Yidong Ge, Ziqing Zhan, Meng Ye et al. (4 authors)
Journal of Molecular Medicine
Published: Mar 2023
2 citations
2 citations
129 days before retraction
Targeting epigenetic regulators to overcome drug resistance in cancers
Nan Wang, Ting Ma, Bin Yu
Signal Transduction and Targeted Therapy
Open Access
Published: Feb 2023
179 citations
179 citations
164 days before retraction
Epigenetic regulator KDM4A activates Notch1-NICD-dependent signaling to drive tumorigenesis and metastasis in breast cancer
Jing Pei, ShengQuan Zhang, Xiaowei Yang et al. (9 authors)
Translational Oncology
Open Access
Published: Dec 2022
10 citations
10 citations
212 days before retraction
The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
Zeyuan Zheng, Jinxin Li, Yankuo Liu et al. (12 authors)
Cancers
Open Access
Published: Oct 2022
47 citations
47 citations
299 days before retraction
Natural antisense transcripts as drug targets
Olga Khorkova, Jack Stahl, Aswathy Joji et al. (6 authors)
Frontiers in Molecular Biosciences
Open Access
Published: Sep 2022
16 citations
16 citations
307 days before retraction
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida et al. (4 authors)
Drug Resistance Updates
Published: Sep 2022
53 citations
53 citations
314 days before retraction
Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer
Nikita Jinna, Padmashree C.G. Rida, Max Smart et al. (7 authors)
International Journal of Molecular Sciences
Open Access
Published: Aug 2022
7 citations
7 citations
356 days before retraction
Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer
Yifeng Mao, Gaowei Yang, Yingbang Li et al. (6 authors)
Cancers
Open Access
Published: Jul 2022
16 citations
16 citations
365 days before retraction
KDM4A promotes the progression of neuroendocrine prostate cancer
Celia Sze Ling Mak, Ming Zhu, Xin Liang et al. (28 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: May 2022
443 days before retraction
Quick Stats
Total Citations:
27
Years Since Retraction:
2.3 years
Open Access:
Yes
Last Checked:
Jul 24, 2025